Novel nanosized GD3+-ALGD-G2 -C595: In vivo dual selective MUC-1 positive tumor molecular MR imaging and therapeutic agent

Journal of Nanomedicine and Nanotechnology

Volumn 3, Issue 7, 2012, Pages 4-

  Mirzaei, Mehdi ^a   Mohagheghi, Mohammadali ^b   Shahbazi Gahrouei, Daryoush ^c   Khatami, Alireza ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84877297295     PISSN: None     EISSN: 21577439     Source Type: Journal    
DOI: 10.4172/2157-7439.1000147     Document Type: Article

References (26)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, et al. (2003) Cancer statistics. CA Cancer J Clin 53: 5-26.
2. Eccles SA, Box G, Court W, Sandle J, Dean CJ, et al. (1994) Preclinical models for the evaluation of targeted therapies of metastatic disease. Cell Biophys 25: 279-291.
3. Rudin M, Beckmann N, Porszasz R, Reese T, Bochelen D, et al. (1999) In vivo magnetic resonance methods in pharmaceutical research: current status and perspectives. NMR Biomed 12: 69-97.
4. Pantel K, Otte M (2001) Occult micrometastasis: enrichment, identification and characterization of single disseminated tumor cells. Semin Cancer Biol 11: 327-337.
5. Mikawa M, Kato H, Okumura M, Narazaki M, Kanazawa Y, et al. (2001) Paramagnetic water-soluble metallofullerenes having the highest relaxivity for MRI contrast agents. Bioconjugate Chem 12: 510-514.
6. Artemov D (2003) Molecular magnetic resonance imaging with targeted contrast agents. J Cell Biochem 90: 518-524.
7. Strable E, Bulte JWM, Moskowitz B, Vivekanandan K, Allen M, et al. (2001) Synthesis and characterization of soluble iron oxide-dendrimer composites. Chem Mater 13: 2201-2209.
8. Winnicka K, Bielawski K, Rusak M, Bielawska A (2009) The effect on generation 2 and 3 poly (amidoamide) dendrimer on viability of human breast cancer cells. J Health Sci 55: 169-177.
9. Bumb A, Brechbiel MW, Choyke P (2010) Marcromolecular and dendrimerbased magnetic resonance contrast agents. Acta Radiol 51: 751-767.
10. Konjevic C, Jurisic V, Spuzic I (1997) Corrections to the original lactate dehydrogenase (LDH) assay for the evaluation of NK cell cytotoxicity. J Immunol Methods 200: 199-201.
11. Geraldes CFGC, Laurent S (2009) Classification and basic properties of contrast agents for magnetic resonance imaging. Contrast Media Mol Imaging 4: 1-23.
12. Haririan I, Shafiee-Alavidjeh M, Khorramizadeh MR, Shafiee-Ardestani M, Ghane ZZ, et al. (2010) Anionic linear-globular dendrimer-cis-platinum (II) conjugates promote cytotoxicity in vitro against different cancer cell lines. Int J Nanomedicine 5: 63-75.
13. Alavidjeh MS, Haririan I, Khorramizadeh MR, Ghane ZZ, Ardestani MS, et al. (2010) Anionic linear-globular dendrimers: biocompatible hybrid materials with potential uses in nanomedicine. J Mater Sci Mater Med 21: 1121-1133.
14. 3+-DTPA-DG: novel nanosized dual anticancer and molecular imaging agent. Int J Nanomedicine 6: 747-763.
15. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein Measurement with the Folin Phenol Reagent. J Biol Chem 193: 265-275.
16. Shahbazi-Gahrouei D, Rizvi S, Williams M, Allen BJ (2002) In-vitro studies of gadolinium-DTPA conjugated with monoclonal antibodies as cancer-specific magnetic resonance imaging contrast agents. Australas Phys Eng Sci Med 25: 31-38.
17. Shahbazi-Gahrouei D, Williams M, Rizvi S, Allen BJ (2001) In vivo studies of Gd-DTPA-monoclonal antibody and Gd-porphyrins: potential MR imaging contrast agents for cancer. J Magn Reson Imag 14: 169-174.
18. Cohen SM, Xu J, Radkov E, Raymond KN, Botta M, et al. (2000) Syntheses and relaxation properties of mixed gadolinium hydroxypyridinonate MRI contrast agents. Inorg Chem 39: 5747-5756.
19. Von Mensdorff-Pouilly S, Gouretvich MM, Kenemans P, Verstraeten AA, van Kamp GJ, et al. (1998) An enzyme- linked immunosorbent assay for the measurement of circu- lating antibodies to polymorphic epithelial mucin (MUC1).Tumour Biol 23: 186-195.
20. Croce MV, Isla-Larrain MT, Capafons A, Price MR, Segal-Eiras A (2001) Humoral immune response induced by the protein core of MUC1 mucin in pregnant and healthy women. Breast Cancer Res Treat 69: 1-11.
21. Shahbazi-Gahrouei D, Roufeh M, Tavakoli MB (2006) Gadoliniumdiethylenetriaminepenta-acetic acid conjugated with monoclonal antibody C595 as new magnetic resonance imaging contrast agents for breast cancer (MCF-7) detection. Iran Biomed J 10: 209-213
22. Shahbazi-Gahrouei D (2009) Novel MR imaging contrast agents for cancer detection. J Res Med Sci 14: 141-147.
23. Giray S, Bal T, Kartal AM, Kizilel S, Erkey C (2012) Controlled drug delivery through a novel PEG hydrogel encapsulated silica aerogel system. J Biomed Mater Res A 100: 1307-1315.
24. Fischer-Durand N, Salmain M, Rudolf B, Dai L, Juge L, et al. (2010) Sitespecific conjugation of metal carbonyl dendrimer to antibody and its use as detection reagent in immunoassay. Anal Biochem 407: 211-219.
25. Wängler C, Moldenhauer G, Eisenhut M, Haberkorn U, Mier W (2008) Antibodydendrimer conjugates: the number, not the size of the dendrimers, determines the immunoreactivity. Bioconjug Chem 19: 813-820.
26. Patri AK, Thomas T, Baker JR Jr, Bander NH (2002) Antibody-dendrimer conjugates for targeted prostate cancer therapy. Polymeric Materials: Sci Eng 86: 130.